114 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
6
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
Icahn School Of Medicine At Mount Sinai
14
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Cellzome
7
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Ambit Biosciences
40
Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity.
China Pharmaceutical University
10
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.
Schrodinger, Inc.
9
Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance.
Acharya & BM Reddy College of Pharmacy
7
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1.
Genentech Inc.
38
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.
Bayer AG
49
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
Abbvie, Inc
21
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.
AstraZeneca
24
Design, Synthesis, and biological evaluation of 7H-Pyrrolo[2,3-d]pyrimidines as potent HPK1 kinase inhibitors.
University of Chinese Academy of Sciences
2
Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy.
Huadong Medicine
13
Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Insilico Medicine Shanghai Ltd
22
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer.
Pfizer Inc.
21
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer.
Insilico Medicine Shanghai Ltd
22
Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors.
Insilico Medicine Shanghai Ltd
1
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly
28
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Bayer AG
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
2
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.
Zhejiang University
53
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
Hangzhou Medical College
33
Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Shanghai Institute of Organic Chemistry
21
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1.
Pfizer
47
Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors.
Shanghai Jiao Tong University
6
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
Smith, Gambrell & Russell
55
Discovery of quinazoline HPK1 inhibitors with high cellular potency.
Emd Serono Research & Development Institute
44
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Shanghai Institute of Materia Medica
33
Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Shanghai Institute of Materia Medica
11
Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
Central China Normal University
1
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Hefei Institutes of Physical Science
32
Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).
Incyte Research Institute
18
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.
Incyte Research Institute
49
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
China Pharmaceutical University
28
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).
Genentech
6
Novel Isoindolone Compounds as HPK1 Inhibitors for Treating Cancer.
Smith, Gambrell & Russell
28
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.
Merck
24
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.
Bristol Myers Squibb
45
Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.
Biogen
9
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University of Florida
2
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.
Takeda Pharmaceutical
95
3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
The Cleveland Clinic Foundation
66
POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
Jiangsu Nhwa Pharmaceutical Co.
195
Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
Merck Sharp & Dohme
1
CRYSTAL FORM OF 7-AZASPIRO[4,5]DECANE-6,10-DIONE COMPOUND AND PREPARATION METHOD THEREFOR
CMS Research & Development PTE
32
PEPTIDYL NITRILE COMPOUND AND USE THEREOF
Shanghai Yidian Pharmaceutical Technology Development Co.
22
PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
Suven Life Sciences
58
Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
Ontario Institute for Cancer Research
24
PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
Ventus Therapeutics U.S.
51
HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS
Chengdu Cynogen Bio-Pharmaceutical Technology
34
Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors
Ildong Pharmaceutical
16
TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS
Oslo Universitetssykehus
106
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
Neurocrine Biosciences
4
Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
Mindset Pharma
5
Amide compound having bet proteolysis-inducing action and medicinal application thereof
Mitsubishi Tanabe Pharma
61
Substituted Tetrazolyl Compounds Useful as T Cell Activators
Bristol Myers Squibb
118
Pharmaceutical compounds for treatment of medical disorders
Achillion Pharmaceuticals
23
1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction
University of Illinois
182
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
Genentech
70
Indolinones compounds and their use in the treatment of fibrotic diseases
Respivert
7
Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
Oblique Therapeutics
68
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
Mission Therapeutics
56
Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
Boehringer Ingelheim International
336
Hormone receptor modulators for treating metabolic conditions and disorders
Ardelyx
15
Non-aromatic difluoro analogues of resorcylic acid lactones
University of North Carolina At Greensboro
4
2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
Merck Sharp & Dohme
22
Alpha-(3,5-dimethoxybenzylidene)-alpha′-hydrocarbyl methylene cyclic ketone and preparation method thereof
Pharmaxyn Laboratories
17
Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications.
Bristol Myers Squibb